Skip to main content

PureTech Health PLC (PRTC)

NASDAQ: PRTC · IEX Real-Time Price · USD
47.60 -3.40 (-6.67%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap1.42B
Revenue (ttm)11.77M
Net Income (ttm)4.57M
Shares Out28.66M
EPS (ttm)-6.76
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume8,472
Open48.76
Previous Close51.00
Day's Range47.50 - 49.48
52-Week Range33.00 - 65.90
Beta0.96
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About PRTC

PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic ...

IndustryBiotechnology
CEODaphne Zohar
Employees250
Stock ExchangeNASDAQ
Ticker SymbolPRTC
Full Company Profile

Financial Performance

In 2020, PRTC's revenue was $11.77 million, an increase of 20.00% compared to the previous year's $9.81 million. Earnings were $4.57 million, a decrease of -98.75%.

Financial Statements

News

PureTech Founded Entity Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary

BOSTON--(BUSINESS WIRE)--PureTech Health announced that its Founded Entity, Vedanta Biosciences, has appointed Dr. Simona Levi as Chief Legal Officer and Corporate Secretary.

1 week ago - Business Wire

Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced the a...

1 week ago - Business Wire

PureTech Founded Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection...

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile and Exercise of $23.8M Option by BARDA

2 weeks ago - Business Wire

PureTech Founded Entity Sonde Health Launches Vocal Biomarker Technology to Monitor Mental Health and Well-Being

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Sonde Health Launches Vocal Biomarker Technology to Monitor Mental Health and Well-Being

2 weeks ago - Business Wire

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 M...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that ...

2 weeks ago - Business Wire

PureTech Founded Entity Akili Announces Topline Results from Shionogi Phase 2 Study in Japan

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili announces topline results from Shionogi Phase 2 study of SDT-001 (Japanese version of AKL-T01).

3 weeks ago - Business Wire

PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysf...

BOSTON--(BUSINESS WIRE)--PureTech Health today announced the publication of a research paper in Nature Metabolism using its Glyph technology platform.

1 month ago - Business Wire

PureTech to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

BOSTON--(BUSINESS WIRE)--PureTech to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

1 month ago - Business Wire

PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vor Biopharma announced that the U.S. Food and Drug Administration has granted Fast Track designation to VOR33.

Other symbols:VOR
1 month ago - Business Wire

PureTech Health plc – Half-Year Report

BOSTON--(BUSINESS WIRE)--PureTech Health (Nasdaq: PRTC, LSE: PRTC) today announces its half-yearly results for the six months ended June 30, 2021.

1 month ago - Business Wire

PureTech Presents Phase 1 Data for LYT-100 at the European Respiratory Society International Congress 2021

BOSTON--(BUSINESS WIRE)--PureTech announced the presentation of the Phase 1 multiple ascending dose & food effect study of LYT-100 at the virtual ERS Congress.

1 month ago - Business Wire

PureTech Founded Entity Akili Enters Strategic Licensing Agreement with TALi, Extending Akili Portfolio and Industry ...

BOSTON--(BUSINESS WIRE)--PureTech's Akili and TALi completed an agreement for Akili to license TALi's technology designed to address early childhood attention impairments.

2 months ago - Business Wire

PureTech Announces the Appointment Julie Krop, M.D., as Chief Medical Officer

BOSTON--(BUSINESS WIRE)--PureTech appointed Dr. Julie Krop as Chief Medical Officer. She will oversee the advancement of PureTech's clinical-stage Wholly Owned Pipeline.

2 months ago - Business Wire

Imbrium Therapeutics To Develop PureTech's Non-Opioid Candidate For Chronic Bladder Condition

Imbrium Therapeutics has exercised a license option to develop PureTech Health plc's (NASDAQ: PRTC) LYT-503/IMB-150 (formerly designated as ALV-107), a non-opioid therapeutic candidate for interstitial ...

2 months ago - Benzinga

PureTech Announces That Imbrium Therapeutics Has Exercised License Option to LYT-503/IMB-150 for Interstitial Cystiti...

BOSTON--(BUSINESS WIRE)--PureTech announced that Imbrium has exercised a license option under the companies' R&D collaboration agreement to develop PureTech's LYT-503/IMB-150.

2 months ago - Business Wire

PureTech: Notice of Half-Yearly Results

BOSTON--(BUSINESS WIRE)--Notice of Half-Yearly Results

2 months ago - Business Wire

PureTech Founded Entity Akili Releases New Gameplay Features in the First and Only FDA-Cleared Video Game Treatment f...

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Releases New Gameplay Features in the First and Only FDA-Cleared Video Game Treatment for Children With ADHD

3 months ago - Business Wire

PureTech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing

3 months ago - Business Wire

Vedanta Biosciences Completes $68 Million Series D Financing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, Inc., a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from ...

3 months ago - Business Wire

PureTech Founded Entity Gelesis, the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar S...

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Gelesis, the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp.

3 months ago - Business Wire

PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem C...

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vor Announces Collaboration with Janssen to Develop eHSC Transplants Combined with a Bi-Specific Antibody Therapy for AML

Other symbols:VOR
3 months ago - Business Wire

PureTech Founded Entity Sonde Health Announces Collaboration with Qualcomm Technologies for Use of Vocal Biomarker Te...

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Sonde Collaborates with Qualcomm Technologies for Use of Vocal Biomarker Technology on Qualcomm Snapdragon Mobile Platforms

3 months ago - Business Wire

PureTech Health To Test LYT-200 / Tislelizumab Combo In Difficult To Treat Cancer

PureTech Health plc (NASDAQ: PRTC) has announced a clinical trial and supply agreement with an affiliate of BeiGene Ltd (NASDAQ: BGNE). The partnership will evaluate BeiGene's tislelizumab, in combinati...

Other symbols:BGNE
3 months ago - Benzinga

PureTech Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate LYT-200 and Tislelizumab in Patients ...

BOSTON--(BUSINESS WIRE)--PureTech Announces Clinical Trial & Supply Agreement with BeiGene to Evaluate LYT-200 & Tislelizumab in Patients with Difficult-to-Treat Solid Tumors

Other symbols:BGNE
3 months ago - Business Wire

PureTech Founded Entity Vedanta Biosciences Announces New Data from Phase 1 Study of VE202 for the Treatment of Infla...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing hi...

3 months ago - Business Wire